India, April 7 -- Polyrizon Ltd. (PLRZ) announced that it has entered into definitive agreements for a $3.5 million registered direct offering and concurrent private placement, providing fresh capital to support the advancement of its proprietary intranasal therapies. The financing is expected to strengthen the company's cash position as it prepares for upcoming clinical milestones.
Polyrizon is developing a hydrogel-based intranasal platform designed to protect patients against airborne viruses, allergens, and other harmful particles by creating a protective barrier in the nasal cavity. This approach aims to reduce exposure and infection risk, offering a novel preventive option in respiratory and allergy care.
As part of its development ...